Anti-angiogenic peptides identified in thrombospondin type I domains
- 14 May 2007
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 359 (1), 63-69
- https://doi.org/10.1016/j.bbrc.2007.05.041
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (NHLBI R01 HL079653)
- National Cancer Institute (P50 CA103175)
This publication has 31 references indexed in Scilit:
- Identification of novel short peptides derived from the α4, α5, and α6 fibrils of type IV collagen with anti-angiogenic propertiesBiochemical and Biophysical Research Communications, 2007
- Regulation of tumor angiogenesis by thrombospondin-1Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Neuroblastoma Angiogenesis Is Inhibited with a Folded Synthetic Molecule Corresponding to the Epidermal Growth Factor-Like Module of the Follistatin Domain of SPARCCancer Research, 2004
- Identification of Novel β1 Integrin Binding Sites in the Type 1 and Type 2 Repeats of Thrombospondin-1Journal of Biological Chemistry, 2004
- Cleavage of the Matricellular Protein SPARC by Matrix Metalloproteinase 3 Produces Polypeptides That Influence AngiogenesisPublished by Elsevier BV ,2003
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002
- Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growthJournal of Cellular and Molecular Medicine, 2002
- Identification of an α3β1 Integrin Recognition Sequence in Thrombospondin-1Journal of Biological Chemistry, 1999
- A Combined Assay of Cell Viability and in Vitro Cytotoxicity with a Highly Water-Soluble Tetrazolium Salt, Neutral Red and Crystal Violet.Biological & Pharmaceutical Bulletin, 1996